AxoGen (AXGN) Scheduled to Post Quarterly Earnings on Thursday

AxoGen (NASDAQ:AXGN - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.10) per share for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.

AxoGen (NASDAQ:AXGN - Get Free Report) last announced its earnings results on Tuesday, March 5th. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.11. AxoGen had a negative net margin of 13.66% and a negative return on equity of 22.38%. The company had revenue of $42.92 million for the quarter, compared to analysts' expectations of $42.70 million. On average, analysts expect AxoGen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

AxoGen Price Performance

AXGN traded down $0.35 on Thursday, hitting $6.52. 232,904 shares of the company's stock were exchanged, compared to its average volume of 407,729. AxoGen has a fifty-two week low of $3.45 and a fifty-two week high of $10.83. The company has a current ratio of 2.89, a quick ratio of 2.14 and a debt-to-equity ratio of 0.71. The firm has a 50-day moving average price of $8.43 and a 200-day moving average price of $7.35. The stock has a market cap of $284.86 million, a price-to-earnings ratio of -12.60 and a beta of 1.03.

Insider Activity at AxoGen

In related news, insider Erick Wayne Devinney sold 4,578 shares of the business's stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $7.68, for a total value of $35,159.04. Following the sale, the insider now directly owns 165,661 shares in the company, valued at approximately $1,272,276.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other news, insider Erick Wayne Devinney sold 4,578 shares of the business's stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $7.68, for a total transaction of $35,159.04. Following the completion of the transaction, the insider now directly owns 165,661 shares of the company's stock, valued at $1,272,276.48. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gregory Gene Freitag sold 25,000 shares of the business's stock in a transaction dated Thursday, March 7th. The stock was sold at an average price of $9.00, for a total value of $225,000.00. Following the transaction, the director now directly owns 271,594 shares of the company's stock, valued at $2,444,346. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 111,201 shares of company stock worth $928,054. Company insiders own 7.21% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on AXGN shares. StockNews.com raised shares of AxoGen from a "hold" rating to a "buy" rating in a research note on Wednesday, February 28th. Cantor Fitzgerald reiterated an "overweight" rating and set a $12.00 price target on shares of AxoGen in a report on Friday, January 19th.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.